Clinical Study of HRS-2129 for Acute Gouty Arthritis

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Acute Gouty Arthritis

In brief

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Key facts

Study ID

NCT07706777

Run by

Shandong Suncadia Medicine Co., Ltd.

People needed

90

Starts

2026-07-01

Expected to finish

2026-11-01

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able and willing to provide a written informed consent
• Subjects requiring Acute gouty arthritis
• Target joint VAS pain score ≥ 50 mm (screening)

You may not qualify if…

• Subjects with a history of severe allergies
• Subjects with nervous system disease
• Subjects with a history of mental illness
• Subjects with abnormal liver and renal function
• Subjects with poorly controlled hypertensive
• QTc：>450ms（male），>470ms（female）
• History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)
• The investigators determined that other conditions were inappropriate for participation in this clinical trial

Where it is running

• The Third Affiliated Hospital of Sun Yat-sen University — Guangzhou, Guangdong, China
• Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School — Nanjing, Jiangsu, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.